News & Events

Learn about what's new with CMC Biologics

Altor BioScience and CMC Biologics Announce Agreement for Manufacture and Validation of Altor’s IL-15 Superagonist Molecule, ALT-803, for use in Phase 3 Clinical Trials


BOTHELL, Washington and MIRAMAR, Florida, U.S.A., April 13, 2017—CMC ICOS Biologics, Inc. (“CMC Biologics”), a global leader in clinical and commercial manufacturing of therapeutic proteins, and Altor BioScience Corporation (“Altor”), a leading developer of novel cytokine-based immunotherapeutics for cancer and infectious diseases, today announced that they have entered into a manufacturing agreement for the cGMP manufacturing of Altor’s ALT-803 molecule for use in Phase 3 clinical trials.

View or Download as a PDF  

Follow Us
Join us on LinkedIn Follow us on Twitter